• BrainStorm Cell Therapeutics Inc., of New York, received the third installment of a 2013 grant from Israel's Office of the Chief Scientist (OCS) for $335,000. The total grant of $729,000 yearly was awarded for development of BrainStorm's NurOwn autologous stem cells for amyotrophic lateral sclerosis.